Is Quarterly Dosing For Teva's Ajovy Enough To Differentiate It From Other CGRP Inhibitors?
The US FDA approved Teva's fremanezumab dosed monthly and quarterly versus Amgen's monthly Aimovig, and will launch at the same price. However, it's packaged as a pre-filled syringe instead of an autoinjector, has a higher rate of injection site reactions and it may launch alongside Lilly's Emgality.
You may also be interested in...
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.
The company said it has captured a roughly 28%-30% share of new prescriptions in the CGRP market with the initial launch of Ajovy, a key future growth driver to offset declining Copaxone sales.
Novartis wants a federal judge to stop Amgen from terminating the companies' agreements around potential migraine blockbuster Aimovig, in which it claims to have invested $870m to date. Amgen wants to go to trial, letting a jury decide whether it can end the partnership – and win damages.